Canopy Immunotherapeutics Publishes Research in Neurology Characterizing Distinct Endotypes of Myasthenia Gravis

Study highlights the role of AChR α and γ subunit-specific autoantibody responses in defining clinically distinct patient populations

‍

Sep 2025

‍

Canopy Immunotherapeutics today announced the publication of research in Neurology describing distinct immunological endotypes within acetylcholine receptor-positive (AChR+) Myasthenia Gravis (MG).

‍

The study demonstrates that immune responses against different AChR subunits are associated with distinct clinical manifestations of disease, including differences in disease severity. These findings provide new insight into the biological complexity of MG and support the growing recognition that patients may be driven by different underlying disease mechanisms.

‍

"This publication reflects our commitment to advancing the scientific understanding of antibody-mediated autoimmune diseases," said Dr. Kfir Oved, Chief Executive Officer and Co-Founder of Canopy Immunotherapeutics. "A deeper understanding of disease biology is essential for developing more precise therapeutic approaches and improving outcomes for patients."

‍

The publication further strengthens Canopy's scientific leadership in Myasthenia Gravis and highlights the company's expertise in the biology of pathogenic autoantibodies, a foundation that underpins its proprietary Reverse Immunization® platform and pipeline of targeted therapies for autoimmune diseases.

‍

Read the publication: Subunit-Specific Immunodominance in Clinically Distinct Endotypes of Acetylcholine Receptor-Positive Myasthenia Gravis

‍

‍

‍